{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:40:58Z","timestamp":1791484858014,"version":"4.3.4"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1524,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1111\/j.1365-2133.2011.10351.x","type":"journal-article","created":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T16:19:29Z","timestamp":1301674769000},"page":"626-632","source":"Crossref","is-referenced-by-count":78,"title":["A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0\u00b71% vs. clobetasol propionate 0\u00b705% in childhood vitiligo"],"prefix":"10.1093","volume":"165","author":[{"given":"N.","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Weinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.R.","family":"Krafchik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,6,30]]},"reference":[{"key":"10.1111\/j.1365-2133.2011.10351.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0738-081X(97)00128-4","article-title":"The epidemiology and genetics of vitiligo","volume":"15","author":"Nordlund","year":"1997","journal-title":"Clin Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10351.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1046\/j.1525-1470.2003.20304.x","article-title":"Epidemiology of childhood vitiligo: a study of 625 patients from North India","volume":"20","author":"Handa","year":"2003","journal-title":"Pediatr Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10351.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0190-9622(98)70194-X","article-title":"Vitiligo","volume":"38","author":"Kovacs","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10351.x-BIB4|cit4","first-page":"981","article-title":"Genetic epidemiology of vitiligo: multilocus recessivity cross-validated","volume":"55","author":"Nath","year":"1994","journal-title":"Am J Hum Genet"},{"key":"10.1111\/j.1365-2133.2011.10351.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1086\/375451","article-title":"A genome-wide screen for generalized vitiligo","volume":"72","author":"Fain","year":"2004","journal-title":"Am J Hum Genet"},{"key":"10.1111\/j.1365-2133.2011.10351.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1087-0024.2004.00825.x","article-title":"Autoimmune aspects of depigmentation in vitiligo","volume":"9","author":"Le Poole","year":"2004","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1111\/j.1365-2133.2011.10351.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0738-081X(97)00126-0","article-title":"Immune mechanisms in vitiligo","volume":"15","author":"Bystryn","year":"1997","journal-title":"Clin Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10351.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1001\/jama.293.6.730","article-title":"New insights and new therapies in vitiligo","volume":"293","author":"Grimes","year":"2005","journal-title":"JAMA"},{"key":"10.1111\/j.1365-2133.2011.10351.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S0738-081X(97)00129-6","article-title":"Vitiligo: a psychologically influenced and influencing disease","volume":"15","author":"Hautmann","year":"1997","journal-title":"Clin Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10351.x-BIB10|cit10","first-page":"1","article-title":"An update on new and emerging options for the treatment of vitiligo","volume":"13","author":"Mahmoud","year":"2008","journal-title":"Skin Therapy Lett"},{"key":"10.1111\/j.1365-2133.2011.10351.x-BIB11|cit11","unstructured":"US Food and Drug Administration News Release (January 19, 2006). FDA Approves Updated Labeling with Boxed Warning and Medication Guide for Two Eczema Drugs, Elidel and Protopic http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/2006\/ucm108580.htm"},{"key":"10.1111\/j.1365-2133.2011.10351.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1530\/eje.0.1430639","article-title":"Prevalence of thyroid disease, thyroid dysfunction and thyroid peroxidase antibodies in a large, unselected population. The Health Study of Nord-Trondelag (HUNT)","volume":"143","author":"Bjoro","year":"2000","journal-title":"Eur J Endocrinol"},{"key":"10.1111\/j.1365-2133.2011.10351.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.3748\/wjg.15.4644","article-title":"A short review of malabsorption and anemia","volume":"15","author":"Fern\u00e1ndez-Ba\u00f1ares","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1111\/j.1365-2133.2011.10351.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJMra010501","article-title":"Immune thrombocytopenic purpura","volume":"346","author":"Cines","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2011.10351.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2133.1977.tb05188.x","article-title":"A double-blind trial of 0\u00b705% clobetasol propionate in the treatment of vitiligo","volume":"96","author":"Clayton","year":"1977","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10351.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/archderm.120.5.631","article-title":"Vitiligo treated with topical clobetasol propionate","volume":"120","author":"Kumari","year":"1984","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10351.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1067\/mjd.2002.126250","article-title":"Topical tacrolimus for repigmentation of vitiligo","volume":"47","author":"Grimes","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10351.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000065845","article-title":"Repigmentation of vitiligo with topical tacrolimus","volume":"205","author":"Smith","year":"2002","journal-title":"Dermatology"},{"key":"10.1111\/j.1365-2133.2011.10351.x-BIB19|cit19","first-page":"158","article-title":"Tacrolimus ointment 0\u00b71% produces repigmentation in patients with vitiligo: results of a prospective patient series","volume":"71","author":"Tanghetti","year":"2003","journal-title":"Cutis"},{"key":"10.1111\/j.1365-2133.2011.10351.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1001\/archderm.139.5.571","article-title":"Successful treatment of vitiligo with 0\u00b71% tacrolimus ointment","volume":"139","author":"Travis","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10351.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jaad.2004.05.036","article-title":"Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases","volume":"51","author":"Silverberg","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10351.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1001\/archderm.139.5.581","article-title":"A double-blind randomized trial of 0\u00b71% tacrolimus vs 0\u00b705% clobetasol for the treatment of childhood vitiligo","volume":"139","author":"Lepe","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10351.x-BIB23|cit23","first-page":"88","article-title":"Topical 0\u00b705% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo","volume":"15","author":"Coskun","year":"2005","journal-title":"Eur J Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10351.x-BIB24|cit24","first-page":"13","article-title":"Topical pimecrolimus versus clobetasol in the treatment of vitiligo","volume":"27","author":"El Goweini","year":"2006","journal-title":"Egypt J Derm Androl"},{"key":"10.1111\/j.1365-2133.2011.10351.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S0738-081X(97)00130-2","article-title":"Clinical features of vitiligo","volume":"15","author":"Hann","year":"1997","journal-title":"Clin Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10351.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0190-9622(03)00786-2","article-title":"Clinical study of repigmentation patterns with different treatment modalities and their correlation with speed and stability of repigmentation in 352 vitiliginous patches","volume":"50","author":"Parsad","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10351.x-BIB27|cit27","first-page":"95","article-title":"Melanin and melanosome complexes in long standing stable vitiligo - an ultrastructural study","volume":"8","author":"Bartosik","year":"1998","journal-title":"Eur J Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10351.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH659>3.0.CO;2-D","article-title":"Melanocytes are not absent in lesional skin of long duration vitiligo","volume":"191","author":"Tobin","year":"2000","journal-title":"J Pathol"},{"key":"10.1111\/j.1365-2133.2011.10351.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0190-9622(96)90690-8","article-title":"Guidelines of care for the use of topical corticosteroids","volume":"35","author":"Drake","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10351.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jaad.2006.08.017","article-title":"High-potency steroid use in children with vitiligo: a retrospective study","volume":"56","author":"Kwinter","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10351.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1525-1470.2010.01223.x","article-title":"The safety and efficacy of tacrolimus ointment in pediatric patients with atopic dermatitis","volume":"27","author":"McCollum","year":"2010","journal-title":"Pediatr Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2011.10351.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2133.2011.10351.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T13:52:01Z","timestamp":1676382721000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/165\/3\/626\/6644240"}},"subtitle":["Tacrolimus vs. clobetasol propionate for childhood vitiligo"],"short-title":[],"issued":{"date-parts":[[2011,6,30]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10351.x","relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6,30]]}}}